Real-world use of an MS blood test shows how it helps monitor disease activity and guide treatment decisions in U.S. patients ...
This segment highlights the role of clinical guidelines in shaping treatment decisions in advanced melanoma, particularly ...
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms ...
The death of a charity supporter who died in hospital after suffering a cardiac arrest may not have happened if she had been ...
The trial compared hospital stay duration of severely burned patients treated with intact fish-skin grafts and patients ...
Chronic constipation is becoming a common issue lately with most people unable to identify the problem on time Learn ...
Add The New York Times on GoogleAgrega The New York Times en Google Some 60 years ago, American legislators set out to tackle ...
Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...
These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
Transformed Medicaid TAF analyses evaluated OUD diagnosis, MOUD receipt, 180-day continuation, and OUD-related ...
Axena Health, Inc., a women's health company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive treatments, today announced a new publication entitled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results